Organization Profile

You just read:

PREVYMIS™ (letermovir) Available in Canada in Late December 2017 for the Prophylaxis of Cytomegalovirus (CMV) Infection in Adult CMV-seropositive Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

News provided by

Merck Canada Inc.

Dec 14, 2017, 13:19 ET